— Exhibition Review —
The 3-day 22nd China World Pharmaceutical Raw Materials Exhibition (CPHI China 2024) came to a successful conclusion on June 21, 2024 at the Shanghai New International Expo Center.
● Exhibition site
Jin Ran Biotech once again appeared at this world-renowned industry event. At the exhibition site, Jin Ran Biotech's booth was crowded with people, and domestic and foreign customers stopped to watch, showing great interest and attention to the chiral compound synthesis technology on display. Jin Ran Biotech uses its leading and unique synthetic biology technology to not only improve the quality and purity of products, but also greatly reduce production costs and environmental pollution, and contribute to the green and sustainable development of the world. In addition, Jin Ran Biotech's strict and perfect quality system ensures the quality and safety of its products, winning the trust and praise of customers.
● Communication and negotiation
During the exhibition, Jinran Bio also had in-depth exchanges and discussions with many customers in the fields of medicine, health products, cosmetics, etc., and established extensive cooperative relationships. These customers spoke highly of Jinran Bio's technical strength and product quality, and expressed their willingness to further strengthen cooperation with Jinran Bio to jointly promote the development of related industries.
● Looking to the future
In short, Jinran Bio's wonderful appearance at the exhibition not only demonstrated its leading and unique technology, but also conveyed its persistent pursuit of green, environmental protection and sustainable development. We have reason to believe that in the future development, Jinran Bio will continue to make greater contributions to the innovation and development of biological synthetic technology.
— Company Introduction—
Founded in June 2020, Jinran Bio is a high-quality green intelligent manufacturing company integrating R&D, production and sales of chiral compounds and materials. Relying on the founding team's more than ten years of experience in the R&D and industrialization of synthetic biology, the company is committed to the design, development, production and sales of new chiral molecules and materials.
The company currently has 4 major technology platforms and 7 product pipelines, and is committed to helping humans realize their desire to create a better life through biosynthesis!
Post time: Jun-27-2024